Alexander E. Denes, M.D., F.A.C.P., joins DAVA Oncology as Medical Director

Feb. 28, 2012 - PRLog -- Dallas, TX – DAVA Oncology, LP is pleased to announce the addition of Alex Denes, MD as a member of the medical oncology support staff. Dr. Denes is from Washington University School of Medicine, where he currently serves as Associate Professor of Medicine. Dr. Denes has an extensive background as a clinician and researcher and joins DAVA’s medical oncology team led by John Eckardt, MD, who serves as Chief Medical Officer.
DAVA Oncology is the only provider of tactical, physician-to-physician accrual enhancement services and strategic drug development products.. DAVA has pioneered the use of medical oncologists and oncology-trained PhDs to provide support for the drug development process in order to accelerate the clinical trial timeline and bring new cancer therapies to physicians and their patients.
The medical oncology support team has extensive experience as clinicians and as principal investigators.  Dr. Eckardt is a board-certified medical oncologist who trained in oncology drug development under Dan Von Hoff, MD. The team also includes Martin Lee, MD, Executive Vice President of Clinical Trial Services, who is a recognized industry expert in clinical trial feasibility and patient recruitment, and Nora Ku, MD, who serves as Senior Medical Director and is board certified in medical oncology, hematology, and internal medicine.

According to Dr. Eckardt, “Alex enhances the current team with his extensive academic and clinical experience.” Furthermore, Dr. Eckardt points out that “Alex, who has served as a principal investigator on many trials as a member of Southwest Oncology Group (SWOG) and the NSABP, has a unique perspective for the team on how to effectively engage and motivate a participating site to accrue patients.”

Medical Oncology support is the competitive advantage and key differentiator that drives DAVA’s accrual enhancement performance. While other recruitment organizations take a patient-centric approach to enrollment by targeting patients with clinical trial education and advertisement, this approach simply is not effective for oncology clinical trials.

DAVA Oncology targets those individuals most influential in the enrollment decision making process--the investigators and research staff responsible for the clinical trial. According to Dr. Eckardt, “in the end, the final decision for a cancer patient to participate in a clinical trial rests on the recommendation of the investigator [and his/her staff] and how it is perceived and acted on by the patient.”
(DAVA)

DAVA Oncology was founded in 2007 with a mission to facilitate successful drug development. Our core strength is our staff of board certified medical oncologists, PhD scientists, and commercial experts, who are able to quickly interpret the evolving and increasingly complex body of oncology scientific information and translate this knowledge into practical drug development plans and accelerated clinical trial execution. DAVA Oncology has a history of product innovation and satisfied customers.

# # #

DAVA Oncology was founded in 2007 with a mission to facilitate successful drug development. During our quest, we have created innovative solutions and services that have accelerated the clinical development process.